Detalhe da pesquisa
1.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662991
2.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469514
3.
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood
; 135(25): 2266-2270, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244251
4.
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
N Engl J Med
; 378(13): 1211-1223, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29590547
5.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Am J Hematol
; 93(11): 1394-1401, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132965
6.
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
Intern Med J
; 52(7): 1286-1287, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35879233
7.
Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.
Haematologica
; 105(2): e76-e79, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171645
8.
Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
Lancet Haematol
; 10(2): e142-e154, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725119
9.
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blood Adv
; 6(20): 5589-5592, 2022 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901282
10.
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Blood Adv
; 6(2): 503-508, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861696
11.
Development of a distributed international patient data registry for hairy cell leukemia.
Leuk Lymphoma
; 63(13): 3021-3031, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36070610
12.
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy.
EJHaem
; 2(2): 266-271, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35845292
13.
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Blood Adv
; 5(20): 4054-4058, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478505
14.
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Blood Adv
; 4(19): 4849-4859, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33031542
15.
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.
Blood Adv
; 4(1): 165-173, 2020 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31935286
16.
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbß3 in mice and humans.
Blood Adv
; 3(24): 4298-4311, 2019 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869418
17.
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Blood Adv
; 8(6): 1439-1443, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231032
18.
Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.
Blood Rev
; 32(6): 499-507, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29709246
19.
Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
Leuk Lymphoma
; 61(10): 2283-2285, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900243
20.
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 60(6): 1572-1575, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30632838